Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.61 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.59 |
| ▸ | NSD2 | O96028 | 2/20 | 0.55 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.55 |
| ▸ | PTPRC | P08575 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.50 |
| ▸ | CDC25B | P30305 | 3/20 | 0.47 |
| ▸ | PTPRF | P10586 | 1/20 | 0.47 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4197326 | 0.83 | PTPN1 (0.52) | PTPN1PARK7NSD2HKDC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4110169 | 0.82 | MEN1 (0.50) | PTPN1PARK7NSD2HKDC1ALDH1A1 | |
| SCHEMBL7580200 | 0.78 | PTPN1 (0.71) | PTPN1PARK7NSD2HKDC1PTPRC | |
| SCHEMBL13611379 | 0.76 | PTPN1 (0.75) | PTPN1PARK7NSD2HKDC1PTPRC | |
| SCHEMBL11322423 | 0.76 | PTPN1 (1.00) | PTPN1PARK7NSD2HKDC1PTPRC | |
| SCHEMBL133451 | 0.76 | PTPN1 (0.53) | PTPN1PARK7NSD2HKDC1PTPRC | |
| SCHEMBL4196479 | 0.72 | MEN1 (0.49) | PTPN1PARK7NSD2HKDC1ALDH1A1 | |
| 4-Amino-[1,2]Naphthoquinone SCHEMBL422308 | 0.71 | PTPN1 (1.00) | PTPN1NSD2HKDC1PTPRCKDM4E | |
| Hydrochloric Acid SCHEMBL4120194 | 0.71 | MEN1 (0.47) | PTPN1PARK7NSD2HKDC1ALDH1A1 | |
| SCHEMBL8600693 | 0.70 | PTPN1 (0.75) | PTPN1NSD2HKDC1PTPRCKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | PROGEN PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CELLGATE, INC. | 2008-08-14 | — | — | US | disclosed |
| US-7279502-B2 | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7253207-B2 | Quinones as disease therapies | CELLGATE, INC. (US) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CTSB, KLK3, FOLH1 | PTPN1 3701/4885PARK7 1541/4885NSD2 2686/4885 |
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CTSB, CTSL, CTSV | PTPN1 4034/4885PARK7 1326/4885NSD2 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.